..
Illumina, Inc.
9885 Towne Centre Drive
San Diego
California
92121-1975
U.S.A.
Phone:
858-202-4500
Fax:
858-202-4545
|
innovative technologies
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Leading-edge products and services
Illumina has developed a comprehensive line of products that address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine. Our offering includes leading-edge solutions for:
SNP genotyping
Copy number variation
DNA methylation studies
Gene expression profiling
Low-multiplex analysis of DNA, RNA, and protein
Our products and services are used by a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.
a collaborative approach
In concert with prospective customers and partners, Illumina takes a highly collaborative approach to business relationships. We're good listeners, value feedback, and believe in working together. Illumina is committed to providing our customers with world-class solutions, service, and support throughout their relationship with us to maximize their scientific success.
Building the illumina community
Staffed with a cohesive mix of high-performing scientists, engineers, managers, and support staff, Illumina is committed to building a team that delivers high-quality products and industry-leading service to the marketplace. Every employee is a critical part of the growing Illumina Community. Through our actions we strive to invite everyone associated with our company to become a part of this community. This includes customers, collaborators, suppliers, and industry colleagues.
Key Management:
Jay T. Flatley
President & Chief Executive Officer
Christian G. Cabou
Senior Vice President & General Counsel
Gregory F. Heath, Ph.D.
Senior Vice President & General Manager, Diagnostics Business Unit
Christian Henry
Senior Vice President, Chief Financial Officer & General Manager, Life Sciences Business Unit
Tristan B. Orpin
Senior Vice President & Chief Commercial Officer
Nicholas J. Naclerio, Ph.D.
Senior Vice President, Corporate Development
Mostafa Ronaghi, Ph.D.
Senior Vice President & Chief Technology Officer
Email:
info@illumina.com
Ownership:
Public
Web Site:
Illumina, Inc.
Employees:
1200+
Symbol: ILMN
|
|
|
Company News |
Illumina, Inc. (ILMN) Launches BaseSpace® Apps
5/16/2013 11:35:44 AM
More...
|
Illumina, Inc. (ILMN) Announces Partnerships to Automate TruSeq® and Nextera® Sample Preparation Kits
5/15/2013 10:28:36 AM
More...
|
Personalis Announces Illumina, Inc. (ILMN) CSPro Certification for Sequencing
5/7/2013 11:02:49 AM
More...
|
Wuhan Kindstar Diagnostics Announces Collaboration With Illumina, Inc. (ILMN)
4/19/2013 11:30:37 AM
More...
|
Bio-Rad Laboratories, Inc. (BIO)'s New ddPCR™ Library Quantification Kit Optimizes Performance of Illumina, Inc. (ILMN) NGS Platforms
4/17/2013 1:45:29 PM
More...
|
Illumina, Inc. (ILMN) to Announce First Quarter 2013 Financial Results on Monday, April 22, 2013
4/8/2013 6:35:13 AM
More...
|
Illumina, Inc. (ILMN) Launches TruSight™ Tumor Content Set
4/4/2013 11:59:22 AM
More...
|
Ambry Genetics Launches FFPE Somatic Variant Profiling Services Developed in Collaboration With Illumina, Inc. (ILMN)
4/4/2013 11:31:34 AM
More...
|
Illumina, Inc. (ILMN) Beats Life Technologies (LIFE) DNA Patent Infringement Claims
3/22/2013 8:39:26 AM
More...
|
Syntrix Wins $96 Million Verdict Against Illumina, Inc. (ILMN) in DNA Patent Suit
3/15/2013 7:11:05 AM
More...
|
|
|
|